An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
PDQ Cancer Information Summaries [Internet].
Bethesda (MD): National Cancer Institute (US); 2002-.
Top results in this bookTable of Contents
Upadacitinib (Rinvoq): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with moderately to severely active Crohn disease who have demonstrated prior treatment failure; that is., an inadequate response to, loss of response to, or intolerance to at least one conventional and/or biologic therapy [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Jan.
CADTH Canadian Drug Expert Committee Final Recommendation Infliximab: (Inflectra — Hospira Healthcare Corporation): Indications: Crohn Disease and Ulcerative Colitis [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Oct 26.
Risankizumab (Skyrizi): CADTH Reimbursement Recommendation: Indication: For the treatment of adults with moderately to severely active Crohn's disease who have an inadequate response, intolerance, or demonstrated dependence to corticosteroids; or an inadequate response, intolerance, or loss of response to immunomodulators or biologic therapies [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 May.
Crohn’s disease: management.
London: National Institute for Health and Care Excellence (NICE); 2019 May 3. (NICE Guideline, No. 129.)
Infliximab (Remsima SC): CADTH Reimbursement Recommendation: Indication: For the maintenance treatment of adults with moderately to severely active Crohn’s disease who have had an inadequate response or were intolerant to conventional therapy. Remsima SC should only be used as maintenance therapy after the completion of an induction period with intravenous infliximab [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 May.
Bimekizumab (Bimzelx): CADTH Reimbursement Recommendation: Indication: The treatment of adult patients with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Jun.
Mirikizumab (Omvoh): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, loss of response, or were intolerant to conventional therapy, a biologic treatment, or a Janus kinase inhibitor [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Dec.
Infliximab (Remsima SC): CADTH Reimbursement Recommendation: Indication: For the maintenance treatment of adults with moderately to severely active ulcerative colitis who have had an inadequate response or were intolerant to conventional therapy. Remsima SC should only be used as maintenance therapy after the completion of an induction period with intravenous infliximab [Internet].
CADTH Canadian Drug Expert Review Committee Final Recommendation: Adalimumab: (Humira — AbbVie): Indication: Ulcerative Colitis [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Apr.
Bimekizumab (Bimzelx): CADTH Reimbursement Recommendation: Indication: For the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Apr.
Ozanimod (Zeposia): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, loss of response, or were intolerant to either conventional therapy or a biologic agent [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022 Dec.
Coeliac Disease: Recognition, Assessment and Management.
London: National Institute for Health and Care Excellence (NICE); 2015 Sep. (NICE Guideline, No. 20.)
CADTH Reimbursement Reviews and Recommendations.
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2013-.
Faecal Incontinence: The Management of Faecal Incontinence in Adults.
London: National Collaborating Centre for Acute Care (UK); 2007. (NICE Clinical Guidelines, No. 49.)
Infant and Young Child Feeding: Model Chapter for Textbooks for Medical Students and Allied Health Professionals.
Geneva: World Health Organization; 2009.
Guideline: Optimal Serum and Red Blood Cell Folate Concentrations in Women of Reproductive Age for Prevention of Neural Tube Defects.
Geneva: World Health Organization; 2015.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on